¼¼°èÀÇ Ã¶ ų·¹ÀÌÆ® ¿ä¹ý ½ÃÀå º¸°í¼­(2025³â)
Iron Chelation Therapy Global Market Report 2025
»óǰÄÚµå : 1769629
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,272,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,065,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,859,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ö ų·¹ÀÌÆ® ¿ä¹ý ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â 34¾ï 6,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, CAGR 6.6%·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº °æ±¸ ų·¹ÀÌ¼Ç Ä¡·áÁ¦ »ç¿ë Áõ°¡, Èñ±ÍÁúȯ ¿¬±¸ÅõÀÚ Áõ°¡, °³º°È­ Ä¡·á Á¢±Ù¹ýÀÇ Á߽à Áõ°¡, ½Å±Ô Ä¡·á¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Áõ°¡, °³¹ßµµ»ó±¹¿¡¼­ÀÇ ÇコÄɾî Á¢±Ù¼º °³¼± µî¿¡ ±âÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â °æ±¸ ų·¹ÀÌÆ® ¾à Á¦Á¦ÀÇ Áøº¸, º´¿ë¿ä¹ý Àü·«ÀÇ ´ëµÎ, Ç¥Àû ¾à¹° Àü´Þ ±â¼úÀÇ Çõ½Å, ö°úÀ×ÁõÀ» °ËÃâÇÏ´Â °íµµÀÇ Áø´Ü µµ±¸ µµÀÔ, ȯÀÚ Áß½ÉÀÇ Ä¡·á ¸ðµ¨ÀÇ ÁøÈ­ µîÀÌ ÀÖ½À´Ï´Ù.

¼öÇ÷ Ƚ¼ö Áõ°¡°¡ ÇâÈÄ ¼ö³â°£ ö ų·¹ÀÌÆ® ¿ä¹ý ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼öÇ÷À̶õ Ç÷¾×·®À» ȸº¹½ÃŰ°Å³ª ºóÇ÷À̳ª ½ÇÇ÷ µîÀÇ º´¼¼¸¦ Ä¡·áÇϱâ À§ÇØ Á¦°øµÈ Ç÷¾×À» ȯÀÚ¿¡°Ô Åõ¿©ÇÏ´Â °úÁ¤À» ¸»ÇÕ´Ï´Ù. ¼öÇ÷ÀÇ Áõ°¡´Â ÁÖ·Î º¹ÀâÇÑ ¿Ü°ú ¼ö¼úÀÇ Áõ°¡¿¡ ±âÀÎÇϰí ÀÖÀ¸¸ç, ¸¹Àº °æ¿ì Ç÷¾× ¼øÈ¯ µ¿ÅÂÀÇ ¾ÈÁ¤À» À¯ÁöÇϰí ȯÀÚÀÇ È¸º¹À» µ½±â À§ÇØ ¼öÇ÷À» ÇÊ¿ä·Î ÇÏ´Â Å« ÆøÀÇ ÃâÇ÷·Î À̾îÁý´Ï´Ù. ö ų·¹ÀÌÆ® ¿ä¹ýÀº ÀæÀº ¼öÇ÷ÀÇ °á°ú·Î ü³»¿¡ ÃàÀûµÇ´Â °úµµÇÑ Ã¶ºÐÀ» Á¦°ÅÇϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ¿¹¸¦ µé¸é, ¹Ì±¹À» °ÅÁ¡À¸·Î ÇÏ´Â ºñ¿µ¸® ´ÜüÀÎ ¹Ì±¹ Àû½ÊÀڻ翡 ÀÇÇϸé, ¹Ì±¹¿¡¼­´Â ¿¬°£ ¾à 1,600¸¸ °³ÀÇ Ç÷¾× ¼ººÐÀÌ ¼öÇ÷µÇ°í ÀÖ½À´Ï´Ù. ³´»óÀûÇ÷±¸ÁõÀº 9¸¸ ¸í¿¡¼­ 10¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡¸ç, ¸Å³â ¾à 1,000¸íÀÇ ¿µ¾Æ°¡ ³´»óÀûÇ÷±¸ÁõÀ¸·Î ž ±× ´ëºÎºÐÀÌ Æò»ý ¼öÇ÷À» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ±× °á°ú ¼öÇ÷ ºóµµÀÇ Áõ°¡°¡ ö ų·¹ÀÌÆ® ¿ä¹ý ½ÃÀåÀÇ È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ö ų·¹ÀÌÆ® ¿ä¹ý ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Ä¡·á È¿°ú¸¦ ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸç ȯÀÚÀÇ ¾îµå·¹½ÌÀ» Çâ»ó½Ã۱â À§ÇØ »ýü ÀÌ¿ë·üÀ» Çâ»ó½ÃŲ Â÷¼¼´ë ų·¹ÀÌÅÍ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼±ÁøÀûÀΠų·¹ÀÌÆ®Á¦´Â Èí¼ö¼º°ú Ä¡·á È¿À²À» ³ôÀ̵µ·Ï ó¹æµÇ°í ÀÖÀ¸¸ç, ö °úÀ×Áõ °ü¸®¿¡ ÀÖ¾î Åõ¿© ·¹Áö¸àÀ» ÇÕ¸®È­Çϰí ÄÄÇöóÀ̾𽺸¦ Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 3¿ù ÀÌÅ»¸®¾Æ Á¦¾àȸ»ç Chiesi Farmaceutici S.p.A.´Â 1ÀÏ 2ȸ º¹¿ëÇÏ´Â ¼­¹æ¼º ö ų·¹ÀÌÆ®Á¦ FERRIPROX MR¿¡ ´ëÇØ »ç¶ó¼¼¹Ì¾Æ, ³´»ó ÀûÇ÷±¸Áõ, ±âŸ ºóÇ÷ ȯÀÚÀÇ Ã¶°úÀ×Áõ Ä¡·áÁ¦·Î ij³ª´Ù º¸°ÇºÎ·ÎºÎÅÍ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. º» Á¦Ç°Àº Èñ±ÍÁúȯ Ä¡·á¿¡ ÀÖ¾î º¸´Ù ³ôÀº ÆíÀǼº°ú Áö¼ÓÀûÀÎ µµ¿òÀ» Á¦°øÇÕ´Ï´Ù. Æä¸®Ç÷Ͻº MR 1,000mgÀº ÀÓ»ó½ÃÇè¿¡¼­ ö°úÀ×Áõ ȯÀÚ¿¡°Ô ¾çÈ£ÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» º¸¿© À¯È¿ÇÏ°í ¾ÈÀüÇÑ °ÍÀ¸·Î Áõ¸íµÇ¾ú½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï ¹× °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Iron chelation therapy is a medical treatment aimed at eliminating excess iron from the body in patients who undergo frequent blood transfusions or suffer from iron overload disorders. This treatment uses chelating agents that bind to surplus iron, enabling its removal from the body through urine or feces. It is commonly used to manage conditions like thalassemia, sickle cell disease, and other chronic anemias to prevent organ damage and improve long-term health outcomes.

The primary types of iron chelation therapy include deferasirox, deferoxamine, and deferiprone. Deferasirox is an oral chelating agent widely used to reduce excess iron in patients receiving regular blood transfusions for conditions such as beta-thalassemia and other chronic anemias. The therapy can be administered via different routes, including oral, parenteral, intravenous, and subcutaneous. Key indications for its application include thalassemia, sickle cell disease, myelodysplastic syndromes (MDS), and non-transfusion-dependent thalassemia (NTDT). It is appropriate for a diverse patient group, encompassing pediatric, adult, elderly, and gender-specific populations, and is utilized across various settings such as hospitals, specialty clinics, homecare environments, and others.

The iron chelation therapy market research report is one of a series of new reports from The Business Research Company that provides iron chelation therapy market statistics, including the iron chelation therapy industry global market size, regional shares, competitors with the iron chelation therapy market share, detailed iron chelation therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the iron chelation therapy industry. This iron chelation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The iron chelation therapy market size has grown strongly in recent years. It will grow from $2.51 billion in 2024 to $2.68 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the increasing demand for safer iron removal treatments, rising global rates of blood transfusions, a growing number of chronic anemia cases linked to genetic disorders, increased healthcare spending in emerging markets, and expanding clinical research into iron chelation therapy options.

The iron chelation therapy market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The projected growth in the forecast period can be attributed to the rising use of oral chelation medications, increased investments in research for rare diseases, a growing emphasis on personalized treatment approaches, more regulatory approvals for novel therapies, and improved healthcare access in developing countries. Key trends anticipated during this period include advancements in oral chelation drug formulations, the emergence of combination therapy strategies, innovations in targeted drug delivery technologies, the introduction of advanced diagnostic tools for detecting iron overload, and the evolution of patient-centric treatment models.

The rising number of blood transfusions is expected to drive the growth of the iron chelation therapy market in the coming years. Blood transfusion refers to the process of administering donated blood to a patient to restore blood volume or treat medical conditions such as anemia or blood loss. The increase in blood transfusions is primarily attributed to the growing number of complex surgical procedures, which often lead to substantial blood loss requiring transfusion to maintain hemodynamic stability and aid in patient recovery. Iron chelation therapy is essential for eliminating excess iron that accumulates in the body as a result of frequent transfusions. For example, according to the American Red Cross, a U.S.-based nonprofit organization, approximately 16 million blood components are transfused annually in the U.S. Sickle cell disease impacts between 90,000 and 100,000 individuals, with nearly 1,000 infants born with the condition each year, many of whom require lifelong transfusions. As a result, the growing frequency of blood transfusions is fueling the expansion of the iron chelation therapy market.

Leading companies in the iron chelation therapy market are concentrating on the development of next-generation chelators with improved bioavailability to enhance treatment effectiveness, minimize adverse effects, and boost patient adherence. These advanced chelators are formulated to increase absorption and therapeutic efficiency, helping to streamline dosing regimens and promote better compliance in managing iron overload conditions. For example, in March 2023, Chiesi Farmaceutici S.p.A., an Italy-based pharmaceutical firm, received approval from Health Canada for FERRIPROX MR, an extended-release iron chelator taken twice daily, for the treatment of iron overload in patients with thalassemia, sickle cell disease, and other forms of anemia. This product offers greater convenience and sustained support for rare disease treatment. Clinical studies have demonstrated that FERRIPROX MR 1,000 mg is both effective and safe for the intended patient population, with a favorable safety profile for those with iron overload.

In September 2024, Mitem Pharma, a pharmaceutical company based in France, acquired the global rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed sum. This acquisition is intended to strengthen Mitem Pharma's position in the iron chelation therapy market and expand its portfolio with a proven treatment for managing iron overload conditions. Novartis AG, headquartered in Switzerland, is a pharmaceutical company that provides iron chelation therapy solutions.

Major players in the iron chelation therapy market are Pfizer Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Zydus Cadila, Balchem, Piramal Pharma Solutions, Vifor Pharma Group, MSN Laboratories, Natco Pharma Ltd., CTX Lifesciences, Nouryon, Tivan Sciences, and Synnat Pharma.

North America was the largest region in the iron chelation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iron chelation therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the iron chelation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The iron chelation therapy market includes revenues earned by entities by providing services such as clinical trial management, personalized treatment planning, drug development, and monitoring iron levels. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron chelation therapy market also includes sales of injectable iron chelators, extended-release formulations, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Iron Chelation Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on iron chelation therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for iron chelation therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The iron chelation therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Iron Chelation Therapy Market Characteristics

3. Iron Chelation Therapy Market Trends And Strategies

4. Iron Chelation Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Iron Chelation Therapy Growth Analysis And Strategic Analysis Framework

6. Iron Chelation Therapy Market Segmentation

7. Iron Chelation Therapy Market Regional And Country Analysis

8. Asia-Pacific Iron Chelation Therapy Market

9. China Iron Chelation Therapy Market

10. India Iron Chelation Therapy Market

11. Japan Iron Chelation Therapy Market

12. Australia Iron Chelation Therapy Market

13. Indonesia Iron Chelation Therapy Market

14. South Korea Iron Chelation Therapy Market

15. Western Europe Iron Chelation Therapy Market

16. UK Iron Chelation Therapy Market

17. Germany Iron Chelation Therapy Market

18. France Iron Chelation Therapy Market

19. Italy Iron Chelation Therapy Market

20. Spain Iron Chelation Therapy Market

21. Eastern Europe Iron Chelation Therapy Market

22. Russia Iron Chelation Therapy Market

23. North America Iron Chelation Therapy Market

24. USA Iron Chelation Therapy Market

25. Canada Iron Chelation Therapy Market

26. South America Iron Chelation Therapy Market

27. Brazil Iron Chelation Therapy Market

28. Middle East Iron Chelation Therapy Market

29. Africa Iron Chelation Therapy Market

30. Iron Chelation Therapy Market Competitive Landscape And Company Profiles

31. Iron Chelation Therapy Market Other Major And Innovative Companies

32. Global Iron Chelation Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Iron Chelation Therapy Market

34. Recent Developments In The Iron Chelation Therapy Market

35. Iron Chelation Therapy Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â